Troxacitabine in acute leukemia

References

• Mansour TS, Jin H, Wang W, et al. Anti-human immunode-ficiency virus and anti-hepatitis B virus activities and toxicites of the enantiomers of 2-deoxy-3-oxa-4-thiocytidine and their 5-fluoro analogues in vitro. J Med Chem 1995;38:1–4.
   PubMed Web of Science ®Google Scholar
• Giles FJ. Troxacitabine-based therapy of refractory leukemia. Expt Rev Anticancer Ther 2002;2(3):261–266.
   PubMedGoogle Scholar
• Balzarini J, Wedgewood O, Kruinig J, et al. Anti-HIV and anti-HBV activity and resistance profile of 2,3-dideoxy-3-thiacyti-dine (3TC) and its arylphosphoramidate derivative CF 1109. Biochem Biophys Res Commun 1996;225:363–369.
   PubMed Web of Science ®Google Scholar
• Mar EC, Chu CK, Lin JC. Some nucleoside analogs with anti-human immunodeficiency virus inhibit replication of epstein barr virus. Antiviral Res 1995; (28):1–11.
   PubMed Web of Science ®Google Scholar
• Coates JA, Cammack N, Jenkinson HJ, et al. (- )-2-deoxy-3-thiacytidine is a potent highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agents Chemother 1992; (36):733–739.
   PubMed Web of Science ®Google Scholar
• Alves AJ, et al. Potent anti-HIV and anti-HBV activites of (- )-L-beta-dioxolane-C and (±)-L-beta-dioxolane-T and their asymmetric synthesis. Tetrahedron Lett 1992;33:6899.
   Google Scholar
• Grove KL, et al. Anticancer activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration. Cancer Res 1995;55(14):3008–3011.
   PubMed Web of Science ®Google Scholar
• Grove KL, Cheng YC. Uptake and metabolism of the new anticancer compound beta-L-(- )-dioxolane-cytidine in human prostate carcinoma DU-145 cells. Cancer Res 1996; 56(18):4187–4191.
   PubMed Web of Science ®Google Scholar
• Siu LL, et al. Activity of (- )-2′-deoxy-3′-oxacytidine (BCH-4556) against human tumor colony-forming units. Ann Oncol 1998;9(8):885–891.
   PubMed Web of Science ®Google Scholar
• Kadhim SA, et al. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models. Cancer Res 1997;57(21):4803–4810.
   PubMed Web of Science ®Google Scholar
• Gourdeau H, et al. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines. Cancer Res 2001; 61(19):7217–7224.
   PubMed Web of Science ®Google Scholar
• Gad WP, et al. Es nucleoside transporter content of acute leukemia cells: Role in cell sensitivity to cytarabine (araC). Leuk Lymphoma 1998;32(1-2):45–54.
   PubMed Web of Science ®Google Scholar
• Owens JK, Shewach DS, Ullman B, et al. Resistance to 1-beta-D-arabinofurano sylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer 1992;52:2389–2393.
   Web of Science ®Google Scholar
• De BJS, Stephenson JJR, Baker SD, et al. Troxacitabine, an L-stereoisomeric nucleoside analogue, on a five times daily schedule: A phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol 2002;20:96–109.
   PubMed Web of Science ®Google Scholar
• Krishnan P, et al. Phosphorylation of pyrimidine deoxynucleo-side analog diphosphates: Selective phosphorylation of L-nucleoside analog diphosphates by 3-phosphoglycerate kinase. J Biol Chem 2002;277(7):5453–5459.
   PubMed Web of Science ®Google Scholar
• Krishnan P, et al. Novel role of 3-phosphoglycerate kinase, a glycolytic enzyme, in the activation of L-nucleoside analogs, a new class of anticancer and antiviral agents. J Biol Chem 2003; (278):36726–36732.
   PubMed Web of Science ®Google Scholar
• Moore LE, Boudinot FD, Chu CK. Preclinical pharmacoki-netics of beta-L-dioxolane-cytidine, a novel anticancer agent, in rats. Cancer Chemother Pharmacol 1997;39(6):532–536.
   PubMed Web of Science ®Google Scholar
• Kukhanova M, et al. L- and D-enantiomers of 2′,3′-dideoxycytidine 5′-triphosphate analogs as substrates for human DNA polymerases. Implications for the mechanism of toxicity. J Biol Chem 1995;270(39):23055–23059.
   PubMed Web of Science ®Google Scholar
• Chou KM, Kukhanova M, Cheng YC. A novel action of human apurinic/apyrimidinic endonuclease: Excision of L-configuration deoxyribonucleoside analogs from the 3′ termini of DNA. J Biol Chem 2000;275(40):31009–31015.
   PubMed Web of Science ®Google Scholar
• Grant S. Ara-C: Cellular and molecular pharmacology. Adv Cancer Res 1998;72:197–233.
   PubMed Web of Science ®Google Scholar
• Gourdeau H, et al. Comparative study of a novel nucleoside analogue (troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity. Cancer Chemother Pharma-col 2001;47(3):236–240.
   PubMed Web of Science ®Google Scholar
• Weitman S, et al. The new dioxolane, (- )-2′-deoxy-3′-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts. Clin Cancer Res 2000; 6(4):1574–1578.
   PubMed Web of Science ®Google Scholar
• Schwartz PM, Haggerty JG, Cheng YC. Beta-L-1,3-dioxo-lane-cytidine: A novel nucleoside that inhibits proliferation and induces differentiation of keratinocytes in vitro. Skin Pharmacol Appl Skin Physiol 1998;11 (4–5):207-213.
   Google Scholar
• Rabbani SA, et al. Effect of nucleoside analogue BCH-4556 on prostate cancer growth and metastases in vitro and in vivo. Cancer Res 1998;58(15):3461–3465.
   PubMed Web of Science ®Google Scholar
• Bouffard DY, et al. Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (troxatyl) and cytarabine in human leukemia cells. Cancer Chemother Pharmacol 2003;52(6):497–506.
   PubMed Web of Science ®Google Scholar
• Orsolic N, et al. Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: Preclinical evaluation. Br J Haematol 2004;124(6):727–738.
   PubMed Web of Science ®Google Scholar
• Belanger K, et al. Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30 minutes infusion every 21 days. J Clin Oncol 2002;20(10):2567–2574.
   PubMed Web of Science ®Google Scholar
• Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York, NY: Marcel Dekker; 1982. p 409–417.
   Google Scholar
• Canova A, Yee L, Baker S. A phase I and pharmacokinetic study of beta-L-dioxalo-cytidine (BCH-4556) administered weekly for 3 weeks every 28 days. Proc Am Soc Clin Oncol 1999;18: 197.
   Google Scholar
• Stephenson JJR, Baker SD, Aylesworth C. A phase I and pharmacokinetic study of BCH-4556, a novel L-nucleoside antimetabolite, on a daily × 5 day every 21-day schedule in patients with solid neoplasms. Ann Oncol 1998;9 (Suppl. 2):156.
   Google Scholar
• Baker SD, Stephenson JJR, Goetz A. Determinants affecting beta-L-dioxoalne-cytidine (BCH-4556) exposure and relationship with toxicity in phase I trials. Proc Am Soc Clin Oncol 1999;18: 197.
   Google Scholar
• Giles FJ, et al. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J Clin Oncol 2001;19(3):762–771.
   PubMed Web of Science ®Google Scholar
• Giles FJ, et al. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J Clin Oncol 2002;20(3):656–664.
   PubMed Web of Science ®Google Scholar
• Lee CKK, et al. Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue. Clin Cancer Res 2006; 12:2158–2165.
   PubMed Web of Science ®Google Scholar
• de Bono JS, et al. Troxacitabine, an L-stereoisomeric nucleo-side analog, on a five-times-daily schedule: A phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol 2002;20(1):96–109.
   PubMed Web of Science ®Google Scholar
• Giles FJ, et al. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leuk Res 2003;27(12):1091–1096.
   PubMed Web of Science ®Google Scholar
• Townsley CA, et al. Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: A trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 2003;21(8):1524–1529.
   PubMed Web of Science ®Google Scholar
• Alvarado Y, et al. Troxacitabine activity in extramedullary myeloid leukemia. Hematology 2002;7(3):179–185.
   PubMedGoogle Scholar
• Giles FJ, et al. Randomized phasestudy of troxacitabinecombined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. J Clin Oncol 2003;21(6): 1050–1056.
   PubMedGoogle Scholar
• Giles FJ, et al. Adaptive randomized study of idarubicin and cytarabine vs. troxacitabine and cytarabine vs. troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol 2003; 21(9):1722–1727.
   PubMed Web of Science ®Google Scholar
• Giles F, et al. Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome. Acta Haema-tol 2002;108(3):164–167.
   PubMed Web of Science ®Google Scholar
• Gourdeau H, et al. Species differences in troxacitabine pharmacokinetics and pharmacodynamics: Implications for clinical development. Clin Cancer Res 2004;10(22): 7692–7702.
   PubMed Web of Science ®Google Scholar
• Feldman EJ, Roboz GJ, Allen-bard SL, et al. Phase I evaluation of troxacitabine administered by continuous infusion in subjects. Blood 2003;873a( abstract 7692).
   PubMedGoogle Scholar
• Roboz GJ, et al. Troxacitabine administered by continuous infusion (CI) is well tolerated and effective in adults with relapsed or refractory acute myeloid leukaemia (AML). J Clin Oncol 2005;23( abstract no. 6597):584.
   Google Scholar
• Vukelja SJ, Lombardo FA, James WD, et al. Pyridoxine for the palmar—plantar erthrodysesthesia syndrome. Ann Intern Med 1989;111:688–689.
   PubMed Web of Science ®Google Scholar
• Lopez AM, Wallace L, Dorr RT. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar—plantar erythrodysesthesia. Cancer Chemother Pharmacol 1999;44: 303–306.
   Google Scholar